Uptake of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and the N-methyl-4-phenylpyridinium ion (MPP+) into fetal mouse brain through the placenta

[1]  J. Langston,et al.  The sensitivity of nigrostriatal dopamine neurons to MPP+ does not increase with age , 1988, Neuroscience Letters.

[2]  R. Kalaria,et al.  Differential Postnatal Development of Monoamine Oxidases A and B in the Blood‐Brain Barrier of the Rat , 1987, Journal of Neurochemistry.

[3]  M. Naoi,et al.  A fluorometric determination of N-methyl-4-phenylpyridinium ion, using high-performance liquid chromatography. , 1987, Analytical biochemistry.

[4]  J. Langston,et al.  Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra , 1987, Brain Research.

[5]  Y. Mizuno,et al.  Long-term effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine content in young and mature mice , 1987, Journal of the Neurological Sciences.

[6]  J. Langston,et al.  Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity? , 1985, Life sciences.

[7]  S. Snyder,et al.  Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. , 1984, European journal of pharmacology.

[8]  G. Breese,et al.  Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. , 1984, The Journal of pharmacology and experimental therapeutics.

[9]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[10]  C. Mytilineou,et al.  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon. , 1984, Science.

[11]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[12]  K. Chiba,et al.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.

[13]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[15]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[16]  G. Breese,et al.  Developmental characteristics of brain catecholamines and tyrosine hydroxylase in the rat: effects of 6‐hydroxydopamine , 1972, British journal of pharmacology.

[17]  H. Kuzuya,et al.  Flavins and monoamine oxidase activity in the brain, liver and kidney of the developing rat , 1969, Journal of neurochemistry.

[18]  H. Wiśniewski,et al.  Localization of alkaline phosphatase activity in endothelia of developing and mature mouse blood-brain barrier. , 1986, Developmental neuroscience.

[19]  R. Levi‐montalcini,et al.  Sympathetic nerve cell destruction in newborn mammals by 6-hydroxydopamine. , 1970, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Konig,et al.  [Blood volume of rat organs and residual amount of blood after blood letting or irrigation; determination with radiophosphorus-labeled erythrocytes]. , 1955, Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie.